In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $56.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Zelin has given his Buy rating due to a combination of factors that highlight Syndax Pharmaceuticals’ promising developments and strategic positioning in the market. The recent investor event at ASH 2025 showcased positive feedback from clinicians regarding the company’s two main franchises, Niktimvo and Revuforj. Physicians expressed growing confidence in the clinical application of these drugs, noting the differentiated biology and potential for earlier integration into treatment protocols, particularly in chronic GVHD and AML.
Furthermore, the real-world adoption of Revuforj in various settings, including relapse, MRD-positive scenarios, and post-transplant maintenance, underscores its versatility and effectiveness. The drug’s ability to achieve early MRD negativity and facilitate transplants was particularly emphasized, suggesting a broader market potential than previously anticipated. Additionally, the safety profile of menin inhibitors like Revuforj was considered manageable, with experts acknowledging the typical nature of observed side effects. These insights, combined with a favorable valuation analysis, reinforce the long-term growth prospects for Syndax Pharmaceuticals.
In another report released yesterday, Barclays also maintained a Buy rating on the stock with a $35.00 price target.
SNDX’s price has also changed dramatically for the past six months – from $11.090 to $19.510, which is a 75.92% increase.